Abstracts tagged "pain"

Abstract Number: 1159 • 2018 ACR/ARHP Annual Meeting
Fat Mass Is Associated with Musculoskeletal Pain in Women : A Three-Year Longitudinal Study
Hyun Ah Kim and Jeong-Im Hong, Hallym University Sacred Heart Hospital, Kyunggi-do, Korea, Republic of (South)
Background/Purpose: Increase in fat mass is correlated with musculoskeletal pain. The aim of this study was to examine the relationship between fat mass and the…
Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Stanley Cohen¹, Ahmed Samad², Elaine Karis², Bradley S. Stolshek², Mona Trivedi², Hao Zhang², Girish A. Aras², Greg Kricorian² and James Chung², ¹Metroplex Clinical Research Center, Dallas, TX, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
Abstract Number: 1558 • 2018 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin Efficacy for Primary Sjögren’s Syndrome Associated Small Fiber Neuropathy
Antoine Gaillet¹, Karine Champion¹, Jean-Pascal Lefaucheur², Herve Trout³, Jean-François Bergmann¹ and Damien Sène⁴, ¹Internal Medicine Department, Lariboisière Hospital, Paris, France, ²Clinical Neurophysiology Unit,, Henri-Mondor Hospital, Créteil, France, ³Pharmacy Department, Lariboisière Hospital, Paris, France, ⁴Lariboisière Hospital, Paris Diderot University, Paris, France
Background/Purpose: To analyze the efficacy and tolerance of intravenous immunoglobulin (IVIG) therapy in 11 patients with primary Sjögren's syndrome (pSS)-associated small-fiber neuropathy (SFN).Methods: Retrospective, single-center…
Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Ana-Maria Orbai¹, Jessica Walsh², Peter Nash³, Lichen Teng⁴, Benoit Guerette⁴ and Rieke Alten⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ³University of Queensland, Brisbane, Australia, ⁴Celgene Corporation, Summit, NJ, ⁵Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
Abstract Number: 1918 • 2018 ACR/ARHP Annual Meeting
Defining Pain That Does Not Interfere with Activities Among Rheumatoid Arthritis (RA) Patients
Yvonne C. Lee¹, Patricia Katz^2,3, Amanda Quebe⁴, Luna Sun⁴, Himanshu Patel⁴, Carol L. Gaich⁴, Natalie Boytsov⁴ and Kaleb Michaud^5,6, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Forward/National Data Bank for Rheumatic Diseases, Wichita, KS, ³University of California San Francisco, San Francisco, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: RA patients differ in the degree to which pain interferes with function. To improve function, an understanding of this diversity is needed. Our objectives…
Abstract Number: 1922 • 2018 ACR/ARHP Annual Meeting
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
James Campbell, Randall Stevens and Peter Hanson, Centrexion Therapeutics, Boston, MA
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin and long-acting, non-opioid analgesic in phase 3 trials for moderate to severe OA knee pain, has demonstrated safety…
Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Janet E. Pope¹, Amanda Quebe², Baojin Zhu², Luna Sun², Carol L. Gaich², Francesco de Leonardis², Anabela Cardoso² and Mark C. Genovese³, ¹St. Joseph's Health Care, Divsion of Rheumatology, London, ON, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…
Abstract Number: 2563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial
Kim A Papp¹, Kenneth B. Gordon², Diamant Thaçi³, Akimichi Morita⁴, Melinda Gooderham⁵, Peter Foley^6,7,8, Ihab G. Girgis⁹, Sudeep Kundu⁹ and Subhashis Banerjee⁹, ¹Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Luebeck, Luebeck, Germany, ⁴Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵SKiN Centre for Dermatology, Queen’s University and Probity Medical Research, Peterborough, ON, Canada, ⁶The University of Melbourne, Melbourne, Australia, ⁷St Vincent’s Hospital Melbourne & Probity Medical Research, Melbourne, Australia, ⁸Skin & Cancer Foundation Inc, Melbourne, Australia, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165, a potent and highly selective oral tyrosine kinase 2 inhibitor, inhibits signal transducer and activator of transcription (STAT)-dependent signalling pathways of interleukin-23 and…
Abstract Number: 2588 • 2018 ACR/ARHP Annual Meeting
Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
Alexis Ogdie¹, Kurt de Vlam², Andrew G Bushmakin³, Joseph C Cappelleri³, Philip J. Mease⁴, Roy Fleischmann⁵, Peter C. Taylor⁶, Valderilio F Azevedo⁷, Lara Fallon⁸, Anna Maniccia⁹ and John Woolcott¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Pfizer Inc, Groton, CT, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Oxford, Oxford, United Kingdom, ⁷Universidade Federal do Paraná, Curitiba, Brazil, ⁸Pfizer Canada, Montreal, QC, Canada, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Collegeville, PA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA), and it is recommended that all randomized controlled trials (RCTs) in patients (pts) with PsA…
Abstract Number: 2544 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Impact of Disease (PSAID12) in Early Psoriatic Arthritis: Pain As One of the Main Determinants of Disease Impact
Kim Wervers¹, Jolanda J. Luime², Ilja Tchetverikov³, Andreas H. Gerards⁴, Marc R Kok⁵, Cathelijne W. Y. Appels⁶, Wiebo L. van der Graaff⁷, Johannes H. L. M. van Groenendael⁸, Lindy-Anne Korswagen⁹, Jozien Veris¹⁰, J.M.W. Hazes² and Marijn Vis², ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Sint Franciscus Vlietland Group, Schiedam, Netherlands, ⁵Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Rheumatology, Amphia Hospital, Breda, Netherlands, ⁷Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Sint Franciscus Vlietland Group, Rotterdam, Netherlands, ¹⁰Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands
Background/Purpose: The Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID12) has been developed to measure impact of Psoriatic Arthritis (PsA) for purposes of monitoring and…
Abstract Number: 2697 • 2017 ACR/ARHP Annual Meeting
Systemic Sclerosis Quality of Life Questionnaire (SScQoL) Captures the Complex Problems Experienced By Patients with Scleroderma
Matylda Sierakowska¹, Stanislaw Sierakowski², Marzena Olesinska³, Marek Brzosko⁴, Piotr Leszczynski⁵, Katarzyna Pawlak-Bus⁵, Bogdan Batko⁶, Piotr Wiland⁷, Maria Majdan⁸, Malgorzata Bykowska-Sochacka⁹, Wojciech Romanowski¹⁰, Aleksandra Zon-Giebel¹¹, Slawomir Jeka¹² and Mwidimi Ndosi¹³, ¹Department of Integrated Medical Care, Medical University of Bialystok, Bialystok, Poland, ²Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Poland, Bialystok, Poland, ³Department of Connective Tissue Disease, National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, ⁴Department of Rheumatology and Internal Diseases, Pomeranian Medical University, Szczecin, Poland, ⁵Department of Rheumatology and Rehabilitation, Medical University in Poznan, Poznan, Poland, ⁶Center of Rheumatology, J. Dietl Hospital in Krakow, Krakow, Poland, ⁷Department and Clinic of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ⁸Department of Rheumatology and Connective Tissue Diseases, Medical University in Lublin, Lublin, Poland, ⁹Dr J. Titz-Kosko Regional Hospital for Rheumatic Diseases in Sopot, Sopot, Poland, ¹⁰Poznan Centre of Rheumatology in Srem, Srem, Poland, ¹¹Silesian Center of Rheumatology, Rehabilitation and Prevention of Disability, Ustron, Poland, ¹²2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ¹³Department of Nursing and Midwifery, University of the West of England, Bristol, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a chronic rheumatic disease that disturbs the patients’ biological, social, emotional spiritual, and physical functioning; resulting in reduced quality of…
Abstract Number: 2824 • 2017 ACR/ARHP Annual Meeting
Sleep and Depression Mediate the Relationship between Pain and Cognitive Dysfunction in Lupus Patients
Teresa A. Lillis¹, Vanessa Tirone¹, Stacy Weinberg², Nisarg Gandhi³, Ailda Nika⁴, Winston Sequeira⁴, Stevan E. Hobfoll¹, Joel A. Block² and Meenakshi Jolly⁴, ¹Behavioral Sciences, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush University Medical Center, Chicago, IL, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Cognitive Dysfunction (CD) is seen among 20-80% of patients with Systemic Lupus Erythematosus (SLE) and adversely affects their quality of life and productivity. Pain,…
Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…
Abstract Number: 614 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Alexis Ogdie¹, Kurt de Vlam², Iain B. McInnes³, Philip J Mease⁴, Philip Baer⁵, Tatjana Lukic⁶, Kenneth Kwok⁶, Cunshan Wang⁷, Ming-Ann Hsu⁷ and Anna Maniccia⁶, ¹Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Baer Weinberg MPC, Scarborough, ON, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), which has also been evaluated in other inflammatory rheumatic diseases…
Abstract Number: 860 • 2017 ACR/ARHP Annual Meeting
Effective Treatment of Persistent Arthritis Pain Requires Co-Modulation of TNF and Type I Interferon
Sarah Woller¹, Tony Yaksh² and Maripat Corr³, ¹Anesthesiology, UCSD, La Jolla, CA, ²Anesthesiology 0818, UCSD, La Jolla, CA, ³Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA
Background/Purpose: Pain persisting beyond the resolution or control of clinical signs of rheumatoid arthritis (RA) decreases quality of life for millions of people. Unfortunately, this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.